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Background: Deoxyuridine 5′-triphosphate nucleotide-hydrolases (dUTPases) are essential for maintaining low
intra-cellular dUTP/dTTP ratios. Therefore, many viruses encode this enzyme to prevent dUTP incorporation into
their genomes instead of dTTP. Among the lentiviruses, the non-primate viruses express dUTPases. In bovine
immunodeficiency virus (BIV), the putative dUTPase protein is only 74 residues-long, compared to ~130 residues in
other lentiviruses.
Results: In this study, the recombinant BIV dUTPase, as well as infectious wild-type (WT) BIV virions, were shown to
lack any detectable dUTPase activity. Controls of recombinant dUTPase from equine infectious anemia virus (EIAV)
or of EIAV virions showed substantial dUTPase activities. To assess the importance of the dUTPase to BIV replication,
we have generated virions of WT BIV or BIV with mutations in the dUTPase gene. The two mutant viral dUTPases
were the double mutant D48E/N57S (in the putative enzyme active site and its vicinity) and a deletion of 36
residues. In dividing Cf2Th cells and under conditions where the WT virus was infectious and generated progeny
virions, both mutant viruses were defective, as no progeny viruses were generated. Analyses of the integrated viral
cDNA showed that cells infected with the mutant virions carry in their genomic DNA levels of integrated BIV DNA
that are comparable to those in WT BIV-infected cells.
Conclusions: The herby presented results show that the two BIV mutants with the modified dUTPase gene could
infect cells, as viral cDNA was synthesized and integrated into the host cell DNA. However, no virions were
generated by cells infected by these mutants. The most likely explanation is that either the integrated cDNA of the
mutants is defective (due to potential multiple mutations, introduced during reverse-transcription) or that the
original dUTPase mutations have led to severe blocks in viral replication at steps post integration. These results
emphasize the importance of the dUTPase-related sequence to BIV replication, despite the lack of any detectable
catalytic activity.
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Cellular deoxyuridine 5′-triphosphate nucleotide-hydrolases
(dUTPases) have an essential role in maintaining low cel-
lular dUTP over dTTP ratios. This is done by catalyzing
the hydrolysis of dUTP into two products, the dTTP
precursor-dUMP, and pyrophosphate (PPi) [1-3]. Conse-
quently, the dUTPase activities lead to low dUTP/dTTP
ratios; thus preventing deoxyuridine misincorporation into
DNA, since most DNA polymerases can utilize dUTP in-
stead of dTTP for DNA synthesis. To keep uracils out of
DNA, it is likely that most free-living organisms, as well as
several DNA viruses (e. g., herpesviruses and poxviruses)
and some groups of retroviruses, encode dUTPases. Thus,
this enzyme is essential for the viability of prokaryotes and
eukaryotes and contributes to host range preferences and
infectivity of viruses [1,4].
The replication of retroviruses heavily relies on the
complex process of reverse transcription, the mechanism
by which the retroviral plus-strand RNA genome is copiedFigure 1 Multiple amino acids sequence alignments of dUTPase prote
was taken from The National Center for Biotechnology Information (EIAV d
GI:9626549; BIV dUTPase GI: 9626219; CAEV dUTPase GI: 266706151; Jembra
T-COFFEE alignment tool (Version_9.03.r1318) [16,17]. The locations of five
alignments of non-primate lentiviruses dUTPase-encoding genes. B. BIV dU
residues (D48E/N57S) and the Δ36 deletion mutation are marked above thinto double-stranded DNA [5]. This process is cata-
lyzed entirely by the viral reverse transcriptase (RT) [6].
While synthesizing DNA, RT is capable of incorporat-
ing dUTP instead of dTTP into the nascent DNA
strands [7,8]. This may explain why retroviral dUTPases
are associated with increasing viral replication effi-
ciency and a better fidelity of DNA synthesis, thus pre-
vent deleterious mutations [9]. Cellular dUTPases are
believed to be cell-cycle regulated with an elevated
activity in dividing cells and a substantially lower ac-
tivity in terminally-differentiated non-dividing cells, such
as macrophages [10,11]. Therefore, the endogenous pools
of dUTP are supposed to be lower in dividing cells
relative to the non-dividing ones. Consequently, retro-
viral dUTPases are advantageous for viral replication in
non-dividing cells rather than in dividing cells [12-14].
Most dUTPases (including the retroviral ones) are homo-
trimers with five conserved sequence motifs [15], see
also Figure 1A.ins in different non-primate lentiviruses. The sequence information
UTPase GI: 157830894; FIV dUTPase GI: 1942421; Visna Virus dUTPase
na (JDV) dUTPase GI:733067). The figure was prepared using the
conserved dUTPase motifs are underlined and numbered. A. Sequence
TPase versus EIAV dUTPase. The conserved mutated BIV dUTPase
e sequences.
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several groups of retroviruses encode dUTPases, while the
others lack this enzyme. The dUTPase-expressing retro-
viruses are the beta-retroviruses and the non-primate
lentiviruses, while other retroviruses (including the pri-
mate lentiviruses) lack a dUTPase-encoding gene. Among
the non-primate lentiviruses, dUTPase-encoding sequences
have been identified in feline immunodeficiency virus
(FIV) [18], equine infectious anemia virus (EIAV) [12],
caprine arthritis-encephalitis virus (CAEV) [13] and visna
virus of sheep [19]. In addition, in the bovine lentivi-
ruses, BIV and Jembrana disease virus (JDV), a homolo-
gous dUTPase-encoding gene is present [20,21] (see also
Figure 1A). Earlier studies revealed that retroviruses, en-
coding defective dUTPases, exhibit delayed replication
kinetics in macrophages due to blocks in their replication
cycle [12,13]. In the case of visna virus, the dUTPase is
also dispensable for the neuro-pathogenicity of the virus
[19] and in the case of CAEV, dUTPase is necessary for
the development of bilateral arthritis lesions in the carpus
of the infected goats [22]. The dUTPase-defective viruses
accumulate in their genome G to A transition mutations
[9,22]. Since primate lentiviruses lack dUTPases, it was
suggested that, as an alternative, they recruit and package
in the virions a cellular uracil DNA glycosylase, designated
UNG [4,23]. This enzyme removes uracils from the syn-
thesized DNA, as part of the base-excision repair pathway.
Although UNG and dUTPase are mechanistically different
enzymes, they both participate in excluding uracils from
DNA. Interestingly, the virion-associated UNG catalytic
activity in human immunodeficiency virus type-1 (HIV-1)
can be replaced by packaging into the virions a heterol-
ogous dUTPase from CAEV [24]. Collectively, these data
suggest that, at least in the case of beta-retroviruses and
some lentiviruses, uracil accumulation in the viral DNA
can be detrimental to critical steps in retroviral life cycle.
An interesting exception to this supposition was recently
reported. It was found that HIV-1 could tolerate, or even
benefits from, non-mutagenic uracil incorporation during
intracellular reverse transcription [25]. Thus, in this case
uracilation of the viral cDNA obstructs the strand transfer
of the DNA ends by the integrase (IN), thereby inhibiting
the suicidal auto-integration side pathway and facilitating
the correct chromosomal integration and, hence, the viral
replication.
All retroviruses encode three “classical” enzymes, namely,
the protease (PR), RT and IN. All are indispensable for the
viral life cycle [5]. Thus, dUTPase is the fourth and lesser
studied retrovirus-encoded enzyme that is found only in
several groups of these viruses. It is not completely clear
why most retrovirus groups can replicate without having
dUTPases, unless these viruses evade the need for such a
viral-encoded enzyme by utilizing the cellular counterpart
(as in the case of utilizing the UNG enzyme). Interestingly,and unlike the other retroviral enzymes, the dUTPase-
encoding gene is situated in retroviruses in two entirely
different locations, suggesting two different evolution
pathways. In the prototype beta-retroviruses (namely,
mouse mammary tumor virus-MMTV and Mason-Pfizer
virus), the gag-pol genes encode three reading frames
(gag, pro and pol) and the dUTPase protein is encoded
by both the gag and pro reading frames. Therefore, the
dUTPase protein is actually a trans-frame protein. To be
more specific, the N-terminal segment (of ~95 residues)
of this protein matches the C-terminal part of the Gag
polyprotein; thus, this segment is precisely identical to the
whole viral nucleocapsid (NC) protein (also known as
p14) [26]. The C-terminus of the dUTPase is encoded by
the 5′-end of the pro gene, ending next to the PR-
encoding segment [27-29]. In these retroviruses, the
dUTPase protein is about 250 residues long. In con-
trast, the gag-pol genes of lentiviruses are composed of
only two reading frames (gag and pol). In the dUTPase-
expressing lentiviruses, the encoding gene is located
within the pol gene, between the RNase H (C-terminal)
portion of the RT and the IN-encoding segment. Thus,
it is conceivable that the dUTPase is a proteolytic prod-
uct of the Gag-Pol polyprotein precursor. Moreover, the
size of the lentivirus-associated dUTPases is about half
(~130 residues) of the beta-retroviral dUTPases. For all
the dUTPase-expressing retroviruses, there is suffi-
cient evidence that, similar to the other three retroviral
enzymes, the dUTPases are packaged into the viral parti-
cles in an enzymatically active form [12,13,22,27,29,30].
The case of BIV and the closely-related JDV [31] is
unique, though they follow the same pattern as the
non-primate lentiviruses [32]. The putative dUTPase-
encoding gene (that shows a limited homology to some of
the conserved motifs in other dUTPases- see Figure 1) is
also located between the RT and IN-encoding genes.
However, the encoded polypeptide is substantially smaller
than the ~130-residues long protein in the other lentivi-
ruses, as it is estimated to be only 74 amino acids long
(Figure 1) [20,21]. This BIV protein lacks some of the five
conserved motifs, characteristic of dUTPases. As far
as we know, no other dUTPase-related protein, in-
cluding all viral, prokaryotic or eukaryotic enzymes, is so
small (ranging in most fully-documented cases between
~130 and ~300 residues). The BIV 74-residues-long poly-
peptide has not been extensively studied and it is not clear
whether it can possess any significant dUTPase enzymatic
activity. On the other hand, it is conceivable that this
dUTPase-related peptide has a biological role, since it is
conserved in both BIV and JDV (Figure 1) [31].
In order to characterize the BIV pol gene products, we
have already studied the recombinantly-expressed RT and
IN enzymes of BIV [20,21]. While engineering the RT-
encoding genome, and due to the low sequence homology
Figure 2 Western analysis of the purified recombinant BIV
dUTPase proteins. The proteins were prepared and purified as
described in Methods and in the text. The proteins were analyzed
by 10% SDS/PAGE and the gels were then underwent western blot
analysis. The blot was treated with 1:500 dilution of rabbit antiserum
prepared against the dUTPase-derived peptide (see Methods). After
blocking the serum-treated blot, it was treated with a 1:10,000
dilution of a secondary donkey HRP-conjugated anti-rabbit IgG
antibody that was purchased from abcam.
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expressed two RT versions. The first one was 546 residues-
long and its C-terminus was located upstream and
adjacent to the 74-residues long dUTPase-related pep-
tide. The second, 620 residues-longer RT version, encom-
passed the dUTPase segment at its C-terminus (designated
BIV RT-dU). Likewise, two BIV IN versions were gener-
ated and studied. The longer form, designated BIV dU-IN,
was 353 residues-long, comprising at its N-terminus the
74 residue dUTPase-related polypeptide. The shorter ver-
sion that lacks the dUTPase segment was 279 residues-
long. In both cases of recombinant RT and IN forms, the
longer, dUTPase-containing enzyme versions were slightly
less active than the shorter versions. Therefore, it is likely
from these in vitro studies with the recombinant proteins
that the dUTPase-related segment is not essential for RT
or IN activities.
The objective of the present study was to further study
the dUTPase-related 74 residues-long peptide of BIV.
First, we have expressed this short protein in bacteria,
and after its purification, it was assayed to find whether
it possesses any detectable dUTPase activity. In parallel,
the other BIV Pol-derived enzymes that are fused to the
dUTPase sequences (namely, BIV RT-dU and BIV dU-
IN) were also tested for this activity. As a positive con-
trol, EIAV dUTPase was also expressed and assayed.
None of the three BIV dUTPase-related proteins showed
any detectable enzymatic activity (whilst the EIAV en-
zyme was highly active). Second, an infectious BIV clone
was used to study the replication in cell cultures of the
WT BIV and two of its dUTPase mutants. Unlike the
WT virus, these two mutant viruses were fully defective
in producing progeny virions, although the integration
of viral cDNA into the host cell genome was apparently
normal.
Results and discussion
Recombinant expression of the lentiviral dUTPases
In order to test whether the WT BIV dUTPase- related 74
residues segment has a detectable dUTPase enzymatic ac-
tivity, we have expressed this recombinant polypeptide in
bacteria with a six-histidine tag at its N-terminus. The
protein was purified using the standard Ni-agarose (NTA)
affinity columns, as was extensively used by us for purify-
ing a variety of retroviral enzymes [20,21,33-37], (see
Methods). As a positive lentiviral dUTPase control, which
was previous confirmed to possess enzymatic activity both
in virions [12] and as a recombinant protein [38], we have
cloned, expressed in bacteria and purified the six-histidine
tagged dUTPase of EIAV (see Methods). Sequence align-
ments of the different dUTPase proteins are shown in
Figure 1. In addition, we have used the two versions of
BIV dUTPase- the RT-dU and dU-IN that were fused to
either RT or IN, respectively, as described earlier [20,21].Western analyses of the SDS-PAGE separated three re-
combinant BIV dUTPase-related proteins (performed
with a rabbit anti-serum against a peptide with residues
48–67 of the BIV dUTPase) are shown in Figure 2. The
purified WT dUTPase was composed of mostly of a ~9 kDa
protein that is in good agreement with the expected mo-
lecular mass (74 residues of the dUTPase plus 8 additional
residues at the N-terminal tail- see Methods). In addition,
there were two minor anti-serum reactive proteins (with
apparent MW values of roughly 28 kDa and 38 kDa).
These minor bands (not detected in the RT-dU and
IN-dU protein preparations) may result from some aggre-
gation of the monomers (possibly to trimers and tetra-
mers). The fused RT-dU and IN-dU proteins with MW
of ~73 kDa and ~41 kDa, respectively, were already
studied by us [20,21]. In addition, we studied the purified
134 + 8 residues-long EIAV dUTPase that was shown to
have a molecular mass value of ~15 kDa (data not shown).
The dUTPase activity of the recombinant proteins
All recombinant dUTPase versions were assayed for their
enzymatic activity. We have employed a highly sensitive
dUTPase assay- the commercially-available dUTPase assay
(PPiLight Inorganic PPi assay, obtained from Lonza) - see
Methods. This assay monitors the hydrolysis of dUTP to
dUMP and PPi by a chain of reactions. In short, in the
presence of AMP, the dUTPase-produced PPi is converted
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by the highly-sensitive assay of luciferase, which gener-
ates bioluminescence in the presence of luciferin. This
produced bioluminescence is directly proportional to the
amount of PPi present and, hence, to the initial dUTPase
activity. The data shown in Figure 3 indicate that in this
assay only the EIAV enzyme has a substantial dUTPase ac-
tivity, while the other BIV dUTPase-derived proteins were
practically inactive. Thus, with equal protein amounts, the
ratios between the activities of EIAV enzyme and the BIV-
derived enzymes is >95. In the specific assay, shown in
Figure 3, we have used 25 ng of each protein. However, in
case of the EIAV enzyme, activity could be detected even
by using substantially-lower amounts of protein -as low as
1 ng (data not shown). To exclude the possibility that the
assay conditions were not suitable for the BIV dUTPase,
we have modified several components in the assay mix-
tures (see Methods). Thus, we have used HEPES buffer in-
stead of Tris, used a wide ranges of MgCl2 concentrations
(1–20 mM), varied the KCl from 12 up to 150 mM, DTT
from 5 up to 20 mM and removed the BSA from the reac-
tions. None of the various modified conditions could
recover any significant traces of BIV dUTPase activity
(data not shown). Collectively, it is quite clear that, under
the in vitro-employed conditions (that are suitable for
EIAV dUTPase), none of the three BIV-related putative
dUTPase versions showed any enzymatic activity.
To be sure that the negative results for the BIV-derived
dUTPases are not due to specific assay method employed,
we have also used another method that takes advantage
on the incorporation by Ex Taq polymerase of dUTP
instead of dTTP in a PCR-based reaction. The dUTP-
containing assay mixtures were first pre-incubated
















Figure 3 The PPiLight pyrophosphate detection assay for the dUTPas
dUTPase activity in purified recombinant proteins. For details, see Methods
37°C for 30 min with dUTP-containing reaction buffer that was then terminperiods, allowing dUTP hydrolysis. After heat inactivation,
a PCR reaction was performed with the dUTPase prod-
ucts and the synthesized DNA was analyzed. In this assay,
there is an inverse correlation between dUTPase levels
and the extent of DNA synthesis. The results show again
that while the recombinant EIAV dUTPase has a substan-
tial dUTPase activity, none of the three BIV dUTPase-
related proteins possess any detectable activity (Additional
file 1: Figure S1). It should be noted that even much
higher amounts (up to 250 ng) of the BIV-derived dUT-
Pase proteins did not yield any detectable activity in this
assay (data not shown).
The dUTPase activity in viral extracts
One possible explanation for the negative results, obtained
for the recombinant BIV-related dUTPases, is that the de-
sign of the recombinantly-engineered proteins was wrong
and, and contrary to the EIAV protein, maybe some im-
portant sequences are missing. Consequently, we have
assayed the enzymatic activity in whole extracts of BIV vi-
rions. Viruses were generated from molecular clones of in-
fectious viruses (see Methods). As a positive control, we
have used EIAV virions. It is evident from Figure 4 that
EIAV virions have indeed a substantial dUTPase activity.
This result is in agreement with previous findings that
non-primate lentiviruses package into their virions an
enzymatically-active dUTPase [12,13,22]. However, the
comparable extract of WT BIV yielded an insignificant
dUTPase activity, barely above the background. In this
specific experiment, the figure obtained for the EIAV ex-
tract was ~21000 RLUs and those for all other extracts
(both BIV and cell extracts) were 400–700 RLUs. One ex-
planation is that BIV does not package into virions the
dUTPase-related protein or maybe some cellular factorse Activity
 Enzymes  
ase BIV dU-IN BIV RT-dU
l Enzyme
e enzymatic activities. This assay was performed to assess the
and the text. 25 ng of each recombinant enzyme were incubated at




















Viral end Cell Extract   
Figure 4 The dUTPase activity in virions and in cell extracts. The PPiLight pyrophosphate detection assay was performed to measure the
dUTPase activity in viral extracts of WT BIV and EIAV, in Cf2Th cells that were chronically-infected by WT BIV (generating ~107 viral particles/ml),
or in uninfected Cf2Th cells. A dUTPase activity was also tested in a complementation assay of recombinant BIV dUTPase and the extract of
uninfected Cf2Th cells. The assay conditions are described in Methods and in the text. All viruses and cells were lysed and then incubated at 37°C
for 30 min with dUTP-containing reaction buffer. Viral extracts were prepared from ~8.8 × 107 viral particles of either EIAV or WT BIV. Viruses were
lysed using 0.5% Triton X-100 in the DMEM-FCS medium. Cell extracts were prepared from the pellets of ~5 × 104 infected or uninfected Cf2Th
cells by disruption in 100 μl of 0.5% Triton X-100 in PBS for 30 minutes on ice (followed by removing the insoluble material at 15000 rpm at 4°C).
The activities in cells were then tested with equal amounts of the appropriate cell extracts. The complementation assay was performed by
incubating 25 ng (in 5 μl) of the purified recombinant BIV dUTPase (the 74-residues version) with 10 μl of uninfected Cf2Th cells extract (prepared
from ~5 × 104 cells). All reactions were initiated by adding the 40 μl of dUTP-containing assay buffer for 30 min at 37°C, followed by heat
inactivation, and then assayed as described in Methods. The shown values were obtained after subtracting the non-specific background
produced with lysis buffer.
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this possibility, we have also tested the dUTPase activity
in extracts of cells chronically-infected with the WT virus.
Again, the discerned activity, above the basal level of unin-
fected cells, was next to nothing. Another possibility for
the lack of the in vitro dUTPase activity of BIV dUTPase
is that cellular factors are required to complement this
protein in order to recover dUTPase activity. Therefore,
we also tested the complementation of the recombinant
74-residues BIV dUTPase by the extract of uninfected
Cf2Th cells. The resulting data do not support this possi-
bility (Figure 4). Taken together, no significant dUTPase
activity is associated with BIV virions (or with the recom-
binant protein). It should be emphasized that the low
levels of dUTPase activity in the extracts of both infected
and uninfected cells apparently represent the normal basal
cellular activity.
The effects of mutations in the dUTPase-encoding gene
on virus infectivity
Based on all results shown so far, the next question arising
is whether the dUTPase-related segment is required at
all for BIV infectivity. To this aim, we have generated
two mutants of the infectious pBIV127 clone, where in
both cases the dUTPase-encoding gene was modified. In
the first clone, two amino acids, D48 and N57, were modi-
fied. The D48 residue, is equivalent to the active site Din homotrimeric dUTPases (within the third conserved
motif, see Figure 1) that is responsible for activating the
catalytic water molecule [39,40]. Residue N57 was muta-
genized, because it is located close to this motif and is
conserved among all tested non- primate lentiviruses
(Figure 1A). Thus, the double mutant, D48E/N57S, was
generated (Figure 1B). In the second mutant BIV clone,
36 residues were removed from the dUTPase (amino
acids 9–44); thus generating a truncated clone, desig-
nated Δ36 (Figure 1B).
BIV-susceptible Cf2Th cells (an adherent epithelial line,
derived from normal fetal canine thymus) underwent
transfections with the DNAs of the two mutant plasmids
as well by the WT BIV- harboring pBIV127 plasmid. As a
positive control, we have transfected the Cf2Th cells with
the infectious EIAV plasmid, pSPEIAV19. All produced
viruses were harvested and their copy number was evalu-
ated by cDNA synthesis, followed by qPCR (Figure 5).
The data show that the release of WT EIAV and BIV
virions were comparable, while there was a minor de-
crease in producing the two BIV mutants. All transfection-
produced virions were collected and equal viral particles
were used to infect the susceptible naive Cf2Th cells (see
Methods).
Two methods were used to assess virus infectivity. The
first was the formation of syncytia of the target cells, as





























Figure 5 The amounts of viral particles produced by transfection.
Wild-type and mutant BIV were produced by transfecting Cf2Th cells
with the viral plasmids. The cells were treated with the following
plasmids: pBIV127 (for WT virus), pBIV127 D48E/N57S or pBIV127
Δ36 (for the two BIV mutants), as described in Methods. In short,
Cf2Th cells (70-80% confluent) were used for transfection by 4
ug DNA/well in 6 well plates with the TurboFect Transfection
Reagent, following the recommended protocols. Cells were harvested
48 hours later and the number of viral particles was evaluated, as
described in Methods. Representative data from three independent
experiments are shown. The BIV virions are marked according to their
dUTPase mutation.
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not induce in this cell line any formation of multinucle-
ated cells (data not shown ), in accordance with previous
data [42]. Therefore, we could not use this criterion for
testing EIAV infectivity. The results presented in Figure 6
show that only WT BIV virions could induce consider-
able syncytia of the infected cells, even after two and a
half weeks (five cell passages), while the two mutant BIV
strains did not lead to any significant syncytia above back-
ground (even after 15 passages, namely 8 weeks of growth).
The quantitative analysis of the produced multinucleated
cells (Figure 6A) confirms this finding (Figure 6B). This
finding suggests that the two mutant viruses were incap-
able of infecting the susceptible cells to any detectable
levels. The lack of virus production by the two BIV mutant
virions was further confirmed by the results shown in
Figure 7. Here, we have used a second method for the
evaluation of the de novo- synthesized and released viral
particles. This highly-sensitive method involves the viral
RNA reverse transcription into cDNA that is followed
by qPCR technique (see Methods). As a positive con-
trol, we tested the infectivity of EIAV. Unlike both
WT viruses, EIAV and BIV, the two dUTPase mutants
of BIV did not produce any detectable amounts of
newly-synthesized and released viral RNA. It should
be also noted that the Cf2Th cells were found in our
hands to be the most appropriate for producing infec-
tious BIV particles by the WT pBIV127 plasmid, since
the other cell lines tested (e.g., 293 T and HeLa) producedafter transfection virions that were incapable of infecting
the Cf2Th cells (data not shown).
The lack of observed replication of the mutated BIV vi-
rions is not fully obvious. First, we could not detect in this
study any dUTPase activity associated with even the WT
protein. Second, the cells used were replicative Cf2Th
cells. Therefore, even if a dUTPase activity would have
been demonstrated, previous studies with other dUTPase-
expressing lentiviruses imply that this enzymatically-active
viral protein is required for viral replication in only non-
dividing cells rather than in dividing cells [12-14].
The presence of the RT, IN and dUTPase proteins in BIV
virions
Since the results presented so far imply that BIV requires
for infectivity the complete dUTPase-related sequence, it
was of interest to see whether the dUTPase peptide is
fused to either RT or IN in the virions. To this aim, we
tested the presence and size of RT and IN proteins in WT
BIV virions by western analyses. This was done using anti-
sera prepared against RT and IN-derived peptides (see
Methods). As controls, we used the BIV-derived recombin-
ant proteins versions, RT, RT-dU IN and dU-IN (Figure 8).
Figure 8A shows the results obtained with the anti-IN
serum. It is apparent that the size of the viral IN is close to
that of the recombinantly-synthesized IN protein and it is
definitely shorter than the recombinant dU-IN version.
Likewise, Figure 8B (obtained with the anti-RT serum)
shows that the viral RT is similar in size to that of the re-
combinant RT and, therefore, is not fused to the dUTPase.
This information suggests that, during virus maturation,
the viral protease cleaves the Pol polyprotein precursor
near the sequences that were expected by us to generate
the unfused final RT and IN proteins [20,21]. However,
after probing similar proteins blots (prepared from the
WT BIV extracts) with the anti-dUTPase sera, no signifi-
cant signals were detected (data not shown); although the
same sera were efficient in detecting all recombinant pro-
teins with dUTPase sequences (see Figure 2). These nega-
tive results were obtained independently with anti-sera
prepared in two separate rabbits (data not shown). This
lack of reactivity of the viral endogenous RT and IN pro-
teins with the anti-dUTPase sera can lend further support
for the absence of dUTPase-related sequences in these
finally processed proteins. However, the free dUTPase seg-
ment was also not detected. This finding may result from
either antibody titers, which are too low for detecting the
viral dUTPase (although the recombinant proteins were
easily detected- Figure 2), or from low undetectable levels
of the dUTPase protein in the virions. Such a low level of
the dUTPase 74-residues protein may result, by itself, from
breakdown of the protein under the conditions used by us.
This alternative is more likely than the option that the pro-

















Syncytia per microscope field 
Figure 6 The effects of infecting Cf2Th cells with the three different BIV versions. The three BIV variants (WT and the two dUTPase
mutants- D48E/N57S and Δ36) were used to infect the Cf2Th cells, as described in Methods. The infection of the cells by BIV was monitored by
the formation of multi-cell syncytia after 10 passages. Since in Cf2Th cells, background syncytia of up to 10 nuclei per multinucleated cell could
be occasionally observed, we have considered as BIV-specific only syncytia with more than 15 nuclei. A. The syncytia were visualized by phase
contrast microscopy and by Hoechst dye for fluorescent staining of cell nuclei. The large, multinucleated giant cell syncytia are highlighted in red.
B. A quantitative presentation of the average number of syncytia in a ×20 magnification microscopic field of the Cf2Th cells that were infected
with WT and dUTPase mutated BIV. The control was performed with growth medium (marked- DMEM). Syncytia, obtained in three independent
experiments and in 10 different microscopic fields from each, were counted.
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whole polyprotein) and only then matures by a restricted
cleavage to the final protein products, which is performed
by the viral protease [5]. It should be also mentioned that
we have failed to detect the presence of the dUTPase pro-
tein in extracts of BIV-infected cells (using the same anti-
dUTPase sera). On the other hand, purified dUTPase
could be detected, even when mixed with cell lysates (data
not shown). Hence, this issue regarding the presence of the
dUTPase protein still needs to be further studied.
The integration of cDNA from WT and mutant BIV into
the genome of BIV-infected cells
The importance of the dUTPase-related gene (or even the
two active site related dUTPase residues D48 and N57)
to BIV infectivity (Figures 7 and 8), raises the question atwhich step viral replication was blocked. To answer this,
we have infected BIV-susceptible Cf2Th cells with equal
BIV virion amounts of the WT, double mutant D48E/
N57S or the Δ36 mutant, then harvested the cellular DNA
and tested this DNA for the presence of integrated BIV
cDNA. First, we have PCR-amplified DNA segments that
span the cDNA-cellular DNA boundaries by using a
known repetitive canine specific sequence, primer N201
[43,44], and a BIV-specific primer (N142) (see Table 1).
Then, reaction products were amplified by nested qPCR
reactions that were carried out with internal BIV-specific
primers (N142 and N143). The results shown in Figure 9
indicate that infection with the two mutant BIV strains
did not cause any reduction in integration levels. To ex-
clude the possibility that BIV cDNA integrations show


























Figure 7 The production of virions after infecting Cf2Th cells.
The cells that were 70-80% confluent were grown in 6 well plates
and then infected with equal amounts (2.5 × 105 viral particles per
infection) of EIAV and of the different BIV variants (WT, D48E/N57S,
Δ36)- all produced by transfection (see Figure 5). All infections were
performed in the presence of 10 μg/ml DEAE-Dextran. The titers of the
viral particles produced 4–6 weeks post-infection were determined,
as described in Methods. The presented data were taken 5 weeks after
infection (namely, 8 cell passages), as described in Methods.
Figure 8 Analysis of the RT and IN proteins present in BIV virions and
BIV proteins were prepared, as described in Materials. The proteins were se
The blots were treated with 1:500 dilution of rabbit antiserum against the B
(B). After blocking the serum-treated blots, they were processed, as describ
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have also performed the experiment with another known
canine repetitive sequence, (designated N207, see Table 1)
[43]. Here again, the levels of integrated cDNAs, synthe-
sized by the two mutant BIVs, were not lower than WT
cDNA (data not shown).
Taken together, the results presented in this manu-
script emphasize the cardinal importance of the dUTPase-
related gene region, and hence possibly the encoded
protein segment, to BIV replication. We could not detect
any dUTPase activity in both the recombinantly-
expressed WT BIV dUTPase protein and in WT BIV
virions. This finding is in contrast with the noticeable ac-
tivity detected in the recombinant EIAV protein and in
the EIAV particles. This result suggests that BIV is essen-
tially different from EIAV (that served in this study as a
dUTPase-positive prototype lentivirus) and, thus, from all
other dUTPase-encoding lentiviruses. On the other hand,
despite the lack of apparent enzymatic activity, mutating
the BIV dUTPase-gene has led to a serious impairment
of virus production. The behavior of BIV can be con-
sidered similar, at least in part, to that expected from
abolishing the dUTPase enzyme in EIAV and other dUTPase-
encoding lentiviruses. However, it was shown that active
dUTPases are required in these viruses for infecting
mostly non-replicating cells (and dividing cells can bethe recombinant proteins. BIV extracts and purified recombinant
parated by 10% SDS/PAGE and detected by western blot analysis.
IV IN-derived peptide (A) or antiserum against the RT-derived peptide
ed in Figure 2 and in Methods.
Table 1 The synthetic oligonucleotides uses in this study
Designations (lengths) Sequences Usage
N5A (36nt) CCATGAGCCATATGGCCCCGTGTAGCCCTCCTGAGG BIV dUTPase cloning
N5B (41nt) CCATGCGAATTCAACAGGTCATGAAGACCTCATCTTTTTGG BIV dUTPase cloning
N6A (33nt) CCATGAGCCATATGCTAGCATACCAAGGCACAC EIAV dUTPase cloning
N6B (32nt) CCTAGCGAATTCCAGAATACTCCTGTACTTCC EIAV dUTPase cloning
N110 (27nt) ATCTCTCATGATCTTCAGTGGCTGAGG BIV sequencing
N111 (26nt) ATGCGGACATGAACAGTACCTAAGCC PCR-based dUTPase assay
N120 (52nt) GAGGTATTACCATGGTAGAGTCAGAGCTACAGCTACAGCTACTTAGCATAGG BIV dUTPase point mutagenesis
N122 (26nt) GAAGGCCATATGCATGGCTCTCTTGG BIV dUTPase deletion mutagenesis
N123 (38nt) GAATGTTACCATGGTAATGGCCTCAGGAGGGCTACACG BIV dUTPase deletion mutagenesis
N124 (43nt) GAATAGTCGACAGGAAATGCGTAGATTGAGGGTGCCTCTAAGG BIV dUTPase point mutagenesis
N126 (28nt) CACAATCCCAGGGAGTTGTAGAAAGAGC BIV sequencing
N142 (20nt) CCTTCAGCTTCCGTTCTTTC BIV (qPCR) 93bp upstream to U3
N143 (19nt) CGGAAGATGTCCCAAAGGA BIV (qPCR) 33bp upstream to U3
N144 (20nt) CTCTAATGGCCACTCAGCAA MLV (qPCR)
N145 (20nt) CCTCCCTGAGATCATCCTGT MLV (qPCR)
N156 (23nt) GACTCTTCTGTTGTATCGGGAAA EIAV (qPCR)
N157 (18nt) GGAAGCAAGGGGCTCAAG EIAV (qPCR)
N162 (21nt) TGCTGGTTTACCGGTTTATTG Plasmid Backbone (qPCR)
N163 (20nt) CAGGCATTTGAGAAGCACAC Plasmid Backbone (qPCR)
N201 (24nt) ATTCTAGAGGCCATTACGGCCTCG Canine repetitive genomic sequence (PCR)
N207 (19nt) GCCCGTCACCCATTCACCC Canine repetitive genomic sequence (PCR)
Linker1-BIV (30nt) TCGAGCACGTGTCTAGAGAATAATTGGGCC Creating pET-22b(+)-PmlI plasmid
Linker2-BIV (22nt) CAATTATTCTCTAGACACGTGC Creating pET-22b(+)-PmlI plasmid
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outcome results most likely from the findings that the en-
dogenous pools of dUTP are substantially lower in divid-
ing cells (relative to the non-dividing ones) due to higher
cellular dUTPases [12-14]. Yet, in the present case of BIV,
all infectivity studies were performed with dividing Cf2Th
cells; hence, under these conditions one could expect to
see only a minor effect of the abolishment of the dUTPase
activity. In an analogous case of a prokaryotic cellular
dUTPase (from Mycobacterium), it was shown that this
protein is essential for cell viability; yet the lack of dUT-
Pase activity is not lethal [45]. To make things even more
confusing, we could not even confirm that the mutated
BIV enzyme lost its activity as a result of the introduced
mutations, since no activity existed even in the WT pro-
tein. In all, the damage to virus production that resulted
from modifying a gene encoding a seemingly-inactive en-
zyme (especially in the case of the double BIV dUTPase
mutant D48E/N57S, where only two conserved residues
were mutated) is puzzling.
So, what is the mode by which the mutations intro-
duced into the dUTPase gene have led to blocking viralreplication? The results presented in Figure 9 show that
the extent of viral cDNA synthesis and the subsequent
cDNA integration into the cellular DNA were not af-
fected by the dUTPase mutations, indicating that the
early steps of the retroviral infection (i.e., cell entry, re-
verse transcription and integration) were quite normal.
Since these steps are known to be affected by an aberrant
proteolytic processing of the viral Gag-Pol polyprotein pre-
cursor [5], it is extremely unlikely that two studied dUT-
Pase mutants could affect this processing. Altogether, the
probable explanation is that either the integrated DNA of
the mutant virions is defective (due to possible multiple
mutations introduced during reverse transcription) or that
the original dUTPase mutations have led to blocks in viral
replications at steps post integration (e.g., transcription,
protein synthesis assembly and budding). At this stage, it
seems to us that the first alternative may be more likely.
This supposition is based on the finding that we could get
newly-synthesized virions by transfecting cells with the
complete, albeit mutated, BIV plasmids, a process that by-
passes the normal retroviral reverse transcription and in-





















BIV Integration Assay 
Figure 9 The presence of WT and mutated BIV cDNAs in the genomic DNA of BIV-infected cells. After transfecting Cf2Th cells by different
proviral vectors, equal amounts of the newly-synthesized virions were used to infect Cf2Th cells. The genomic DNA of the infected cells was extracted
and used as a template for PCR reaction using the repetitive canine primer, designated N201 [44] and an endogenous BIV primer (N142). Then, the
amplified genome fragments were used as a template for qPCR reactions with the BIV-specific primers N142 and N143 (Table 1), in order to assess viral
integration (WT and mutated BIV) into the cell genome. Uninfected cells genome was used as a mock control. For technical details, see Methods.
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[32]. Therefore, another potential explanation for the en-
igma surrounding BIV dUTPase could be that the DNA
sequences in the dUTPase-encoding gene of BIV are im-
portant for viral infectivity, because they may overlap
parts of the alternatively-spliced genes that encode the
small regulatory viral protein. Nonetheless, the presently-
predicted genetic map of BIV implies that none of these
regulatory/accessory genes of BIV (i.e., vif, tat, rev, vpy,
vpw, and tmx) can overlap the dUTPase gene [32]. Further
biochemical research will be required to substantiate this
conclusion. Alternatively, it might be possible that the
dUTPase sequence interacts with other viral and/or cellu-
lar factors that participate in the viral replication cycle.
These outlined alternatives and questions lead the way for
future studies to elucidate the molecular mechanisms
underlying the importance of the dUTPase-related gene
to BIV infectivity.
Conclusions
Non-primate lentiviruses express a dUTPase enzyme that
is important for viral growth in non-replicating cells. In
BIV, the dUTPase-expressing gene encodes a putative pro-
tein that is smaller by about half than all known lentiviral
dUTPases. We show herein that, as could be expected
from the presence of a truncated dUTPase, the recombin-
ant BIV protein is devoid of any dUTPase activity. Accord-
ingly, unlike other non-primate lentiviruses, no dUTPase
activity was also detected in BIV virions. Surprisingly, a
modification of the dUTPase gene, leading to the change
of merely two residues at the putative catalytic site and at
vicinity, resulted in totally-defective viruses, although both
viral cDNA synthesis and integration were apparently un-
harmed. These results emphasize the critical importance of
the dUTPase-related sequence to BIV replication, despitethe lack of any catalytic activity, and raise the possibility
that functions, additional to dUTPase activity per se, are
also critical to lentiviral replication.Methods
Synthetic oligonucleotides
All oligonucleotides used in this study are described in
Table 1.Plasmids
BIV and EIAV viral plasmids
1. BIV plasmid: designated pBIV127, which contains the
complete infectious proviral DNA clone of BIV [46] was
already used by us in the studies of BIV RT and IN en-
zymes [20,21].
2. EIAV plasmid: designated pSPEIAV19, contained
the entire infectious EIAV proviral DNA [47]. Both viral
plasmids were generously provided by the “NIH AIDS
Research & Reference Reagent Program”.Other plasmids
The pET22b(+)- vector (from Novagen) was used for sub-
cloning of the BIV dUTPase fragment employed for muta-
genesis of the protein (see below).Bacterial expression plasmid
The pT5M-NdeI-6His plasmid, which is a derivative of
the pT5-NcoI-6His plasmid that was used frequently by
us [20,21,33,37,48,49], was generated by replacing the
NcoI site with a NdeI (both containing the initiation
ATG). This plasmid adds the sequence MHHHHHH- to
the N-terminus of the expressed proteins.
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Recombinant BIV RT-dU and BIV dU-IN were expressed
and purified as described in detail earlier by us [20,21].
Antibodies
The commercial antibodies used were: monoclonal mouse
anti-6HIS horseradish peroxidase (HRP) - conjugated
antibody (from Sigma) and donkey HRP-conjugated anti-
rabbit IgG antibody (purchased from abcam). The anti-
peptide antibodies were prepared in rabbits against syn-
thetic peptides derived from the BIV dUTPase, RT and IN
proteins. All peptides and the antisera were prepared
by Genemed Synthesis. The dUTPase-derived peptide
has the sequence CDSELQLQLLNIGTEHIRIQK, the IN-
derived peptide is CVERAHRDLKDRLAAY and the RT-
derived peptide is NRDDHKQIVQEIRDKLGSC.
Bacteria
BL21(DE3)pLysS
This E. coli strain was used for expressing the recombin-
ant proteins.
DH5α
This E. coli strain was used for standard cloning applica-
tions and plasmid amplifications.
Cell lines
Cf2Th cells
This adherent epithelial cell line (kindly provided by Prof.
L. Sherman) is derived from normal fetal canine thymus
and was found to be susceptible to transfection, infec-
tion and proliferation by BIV and EIAV [41,50]. These rep-
licating cells were grown in Dulbecco’s modified eagle’s
medium (DMEM) supplemented with 10% heat-inactivated
fetal calf serum (FCS), 2% L-glutamine and 1% penicillin-
streptomycin antibiotics. Cells were maintained at 37°C in a
humidified atmosphere of 95% air and 5% CO2.
Construction of the dUTPase-expressing vectors
The fragments of EIAV dUTPase and BIV dUTPase
were first synthesized by PCR, using primer sets N5A/
N5B and pBIV127 (for BIV dUTPase) or N6A/N6B and
pSPEIAV19 (for the EIAV protein). All primers are de-
scribed in Table 1. Reactions were carried with 200 μM of
each dNTP and 2.5 units of Ex Taq polymerase (TaKaRa).
They were first incubated at 95°C for 4 min following this
procedure: denaturation at 95°C for 30 sec, annealing
at 55°C for 30 sec and elongation at 72°C for 60 sec.
This was done for 28 consecutive cycles. The result-
ing dUTPase-encoding genes were designed to include
a NdeI at the 5′ end and an EcoRI site after the terminator
codon. These DNAs were digested with NdeI and EcoRI,
and then ligated into the NdeI and EcoRI-cleaved pT5M-
NdeI-6His expression plasmid (see above). The designationsof the created plasmids were: pT5-6His-BIV-dUTPase and
pT5-6His-EIAV-dUTPase (for BIV dUTPase and EIAV
dUTPase, respectively). Since the putative sequence of
viral BIV dUTPase (see Figure 1) starts with PCSPPE-, the
final amino terminus of this protein is: MHHHHHHM-
PCSPPE-, i. e., 8 extra residues were added to the authen-
tic viral protein. The EIAV protein starts with MLAYQG-;
therefore, the final N-terminus is MHHHHHH-MLAYQG-
(7 residues added, since the authentic proteins starts with a
Met). The authenticity of the inserted fragment was con-
firmed by sequencing the cloned genes.
Recombinant expression and detection of the BIV and
EIAV-derived dUTPases
Escherichia coli BL21(DE3) cells were transformed by the
newly-generated expression plasmids, pT5-BIV-dUTPase
for wild-type (WT) BIV dUTPase and pT5-EIAV-dUTPase
for WT EIAV dUTPase. The proteins were expressed as
follows: a single-transformed colony was grown in 10 ml of
LB medium, containing 100 μg/ml ampicillin, at 37°C with
shaking at 250 rpm. After overnight growth, 500 μl of cul-
ture was transferred to 2 L of fresh LB medium for growth
at 37°C. At OD600 = ~0.6 IPTG was added to a final con-
centration of 1 mM. The culture was further grown for
additional 4 hours at 37°C. Aliquots of the induced bacteria
were removed and their total protein content was ana-
lyzed by sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis (SDS-PAGE). Since all expressed proteins
contained the six-histidine sequence, protein expressions
were confirmed by SDS PAGE of the bacterial extracts
that were followed by western analyses, using monoclonal
anti-6HIS HRP conjugated antibody (Sigma).
Purification of the EIAV and BIV dUTPases
Cell lysis
The cells from the induced medium were harvested by cen-
trifugation at 8000 rpm for 5 min (in a Fiberlite F13-
14X50cg rotor in a Sorvall RC6 Plus centrifuge). Cell lysates
were prepared from the cell pellets from 2 L cultures by sus-
pending the cells into 30 ml of lysis buffer - 50 mM Tris–
HCl pH 8.0, 50 mM NaCl, 1 mM EDTA, 10% glycerol, 10%
sucrose, 5 mMMgCl2, 1 mM DTT, 1 mM phenylmethylsul-
fonyl fluoride (PMSF), 0.5% Triton X-100, 1 mg/ml lyso-
zyme and 10 μg/ml DNase I (Roche). After adding this
buffer, the mixture was stirred at 4°C for 30 min and then
underwent sonication. The lysed bacterial suspensions were
centrifuged at 13,000 rpm for 30 min at 4°C. The soluble
clear fractions were collected and the proteins were analyzed
by SDS-PAGE and by western blotting, using monoclonal
anti-6HIS HRP-conjugated antibody (data not shown).
Protein purification
The bacteria lysates, containing different dUTPases, were
loaded onto a Ni-NTA Agarose columns (Qiagen) (2 ml
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buffer: 50 mM NaH2PO4, 150 mM NaCl, 5 mM imidazole,
final pH 8. The columns were then washed with 50 ml of
this washing buffer. Finally, elution was performed with
20–500 mM imidazole linear gradients in the same buffer
[37,48,49,51]. The purity of the column-eluted dUTPase
enzymes were assessed by SDS-PAGE and western analysis
with monoclonal anti-6HIS HRP- conjugated antibodies
(from Sigma). Protein concentrations were determined by
the Bradford method, using BSA as a standard. After pro-
tein analyses, all pooled protein fractions were aliquoted
and stored at -80°C.
Enzymatic assay for detecting dUTPase activities
We have assessed the dUTPase-dependent production
of inorganic pyrophosphate (PPi) by a chain of reactions.
This method was used to assay the dUTPase activity in
both the purified recombinant proteins as well as in BIV
and EIAV virions. The dUTPase-produced PPi was moni-
tored with the highly-sensitive non-radioactive biolumin-
escent assay, the “PPiLight Pyrophosphate Detection Kit”
(from Lonza, Rockland, USA). The viral dUTPase hydro-
lyzes dUTP to dUMP and PPi. The detection reagent
catalyzes the conversion of AMP and the enzymatically-
produced PPi to ATP. Then, the assay uses luciferase,
which produces light from the newly formed ATP and lu-
ciferin. The initial dUTPase reactions were performed in
40 μl volumes containing 50 mM Tris–HCl, pH 7.5,
20 mM MgCl2, 20 mM KCl, 5 mM DTT, and 0.1 mg/ml
BSA with 100 μM high purity dUTP. To this mixture,
1 ng to 25 ng of the purified dUTPase proteins or 3.5 ×
106 - 8.8 × 107 lysed BIV or EIAV viral particles were
added. This was followed by initial incubations at 37°C for
30 min followed by treatments for 3 min at 95°C. After
this initial dUTPase reactions, 20 μl of PPiLight convert-
ing reagent were added to the whole 40 μl of the dUTPase
reaction products in black wall 96 well plates (Corning).
The mixtures were incubated at room temperature for
30 min; then 20 μl of PPiLight detection reagent were
added and incubated for 30 min. Finally, luminescence
was measured using Mithras LB 940 Multimode Micro-
plate Reader (Berthold Technologies). In all experiments,
the produced relative luminescence units (RLUs) are dir-
ectly proportional to concentrations of the dUTPase-
produced PPi.
Mutagenesis of the infectious BIV-containing plasmid
For these studies, the pET-22b (+) plasmid was modified
by adding a synthetic DNA linker that adds the PmlI re-
striction site. This linker is composed of the two synthetic
oligos, designated linker1-BIV and linker2-BIV (see in
Table 1). The formed duplex, which has pre-formed ApaI
and XhoI sites was ligated into the ApaI and XhoI pre-
digested pET-22b(+) plasmid; thus generating the pET-22b(+)-PmlI plasmid. The pBIV127 DNA was digested
with ApaI and PmlI and a 3813-bp fragment, containing
the putative dUTPase sequence, was isolated and sub-
cloned into the ApaI and PmlI- predigested pET-22b
(+)-PmlI, thus creating the pET-22b(+)-WT dUTPase
vector.
The mutated dUTPase genes were first subcloned into
pET-22b(+)-WT dUTPase plasmid. To create the double
mutation (D48E/N57S) and a deletion mutation (Δ36) in
the dUTPase gene, parts of the WT sequence were amp-
lified by PCR using N120/N124 and N122/N123 muta-
genesis primers, for the double mutant and the deletion
mutant, respectively. Subsequently, the generated double
mutant gene was digested by NcoI and SalI and subcloned
into the NcoI and SalI pre-digested pET-22b(+)-WT dUT-
Pase vector (generating the pET-22b(+)-D48E/N57S dUT-
Pase vector). Similarly, the deletion mutant was created by
NcoI and SalI digestion following ligation into the NcoI
and SalI pre-digested pET-22b(+)-WT dUTPase vector
(generating the pET-22b(+)-Δ36 dUTPase vector). The
validity of the subcloned amplified dUTPase genes was
confirmed by DNA sequencing.
To introduce the mutated dUTPase-encoding DNA
fragments back into the provirus pBIV127, the two mu-
tated pET-22b(+)-dUTPase DNA clones were digested
with ApaI and PmlI and ligated into the ApaI and PmlI
pre-digested proviral pBIV127 vector. The final proviral
BIV vectors were designated pBIV127 D48E/N57S (for the
dUTPase double mutant plasmid) and pBIV127 Δ36 (for
the Δ36 deletion mutant). The modified dUTPase-encoding
sequences were confirmed by DNA sequencing.
DNA transfections and generation of wild-type and
mutant BIV and EIAV
WT pBIV127 and the two mutated BIV proviral plasmids,
as well as pSPEIAV19 (the WT EIAV proviral plasmid) were
used to transfect Cf2Th cells, employing the TurboFect Cell
Transfection Reagent (from Fermentas). According to the
manufacturer’s instructions, 4 μg of each DNA were mixed
with 6 μl of TurboFect reagent in a final volume 400 μl
of DMEM-FCS. The ~80% confluent Cf2Th cells in 6
well plates were supplemented with 4 ml of DMEM-FCS
complete medium and incubated with the TurboFect -DNA
mixture for 18 hours. The medium was then removed and
cells were washed twice with 5 ml of phosphate-buffered
saline (PBS). To check virus titers, the transfected cells
were cultured in DMEM-FCS medium for 24, 48, 72, 96 or
120 hours. At each time point, the medium was removed,
centrifuged for 60 min 5000 g at 4°C, filtered through a
0.45 μM Millipore filter and HEPES buffer (pH 7.6) was
added to a final concentration of 20 mM. The virus-
containing medium was frozen in liquid nitrogen and
stored at −80°C. The number of BIV or EIAV particles in
the medium was analyzed afterwards, as described below.
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About 80% confluent Cf2Th cells in 100 mm plates were
incubated with BIV or EIAV virions (WT and mutants) for
6 hours in the presence of DEAE-Dextran (10 μg/ml). The
cells were incubated at 37°C to permit virus adsorption.
Then, to remove unbound virus and traces of provirus
plasmids, washing were performed three times with 5 ml
PBS. Cells were then supplemented with 10 ml of DMEM-
FCS medium. Mock-infected cells were treated similarly
but with no virus. Next, the BIV-infected cells were sub-
cultured into a new 100 mm plate at 1:3 split for 6–12
passages (done every 3–4 days). Every passage, the cells
were re-fed by removing two-thirds of the supernatant
and replacing it with fresh medium, while being moni-
tored visually for the formation of syncytia. At specified
times, supernatants were removed, centrifuged for 60 min
5000 g at 4°C, and filtered through a 0.45 μM Millipore
filter and 20 mM HEPES buffer (pH 7.6) was added.
Subsequently, the virus-containing medium was frozen in
liquid nitrogen and stored at -80°C. The numbers of viral
particles in the medium were analyzed afterwards, using
the combination of reverse transcribed viral RNA that was
followed by the qPCR of the cDNA products, as described
below.
Preparation of BIV or EIAV virions
For each round of ultracentrifugation, 30 ml of viral super-
natant was centrifuged at 20,000 rpm for 90 minutes at
4°C in a Beckman SW28 swinging bucket rotor in over
20% sucrose “cushions” in TNE buffer (50 mM Tris–HCl,
pH 7.4, 100 mM NaCl and 0.1 mM EDTA). The pellets
were gently re-suspended in 200 μl DMEM-FCS medium
(supplemented with 20 mM HEPES, pH 7.6). The concen-
trated virions were then stored at -80°C.
Viral RNA purification and qPCR analysis
Frozen 200 μl BIV or EIAV virus samples, which were
collected after transfection or infection, were used to
compare viral particle productions. A constant amount
of 5 μl virions of murine leukemia virus (MLV) (~2 × 107
virus particles/ml, calculated by qPCR assay and stand-
ard curve analysis) was added to each sample to serve as
internal efficiency controls for the viral RNA purification
and cDNA synthesis steps. The presence of MLV cDNA
was monitored using primers N145 and N145 (Table 1).
Total viral RNA was extracted from the medium using a
“High Pure Viral RNA Kit” (from Roche). The detailed
extraction and elution procedures are described in the
Roche products instruction manual. Prior and post RNA
extraction, the samples were treated with RNase-free
DNase I (Fermentas) to eliminate any provirus-containing
plasmid contaminations. After this DNase I digestion, the
enzyme was inactivated by incubation at 65°C for 10 min.
3 μl of DNase I-treated viral RNA was used as a templatefor the syntheses of viral cDNAs, as described in Roche
product instruction manual (Transcriptor Universal cDNA
Master).
The synthesized viral cDNAs solutions were diluted in
ultra-pure nuclease free water (at the ratio of 1:50) and
used as a template for qPCR reactions (with FastStart
SYBR Green Master Roche). The qPCR reactions were
performed in 96-well blocks with Applied Biosystems
StepOnePlus™ Real-Time PCR Systems using FastStart
SYBR Green Master (Roche). The sequences of virus-
specific primer sets that were chosen to quantify total
number of viral particles are shown in Table 1. A set of
plasmid (pBIV127) backbone-specific primers (oligos
N162 and N163) was used as controls to exclude possible
plasmid contaminations in the obtained cDNA samples.
For each primer set, an appropriate provirus plasmid was
chosen to create a 10-log-fold standard curve for direct
quantification of all samples. Based on these standard
curved, the amounts of viral particles were calculated.
Each qPCR contained 10 μl of 2XFastStart SYBR Green
Master mix, 4 μl of H2O, 4 μl of a 2 pmol/μl of the specific
primer mix for each BIV sample (N142 and N143, derived
from the sequence located 93–33 nts upstream to the U3,
see Table 1) and 2 μl of diluted viral cDNA. The cycling
conditions were as follows: 95°C for 10 min; and 40 cycles
of 95°C for 10 sec and 59°C for 30 sec. At each cycle, accu-
mulation of PCR products was detected by following the
increase in fluorescence of the reporter dye, double-
stranded DNA-binding SYBR Green. Following amplifica-
tion, melting temperature analysis of PCR 60-nts long
products was performed to determine the specificity of
the PCR. Melting curves were obtained from 55-90°C,
with continuous fluorescence measurements obtained at
every 1°C increase in temperature. All reactions were car-
ried out in triplicates and a non-template control was per-
formed in every analysis. In addition, the concentration of
each virus preparation was calculated for each reaction,
and the mean, standard deviation and statistical signifi-
cance were determined.
Analyses of integrated cDNA into the cellular genomic DNA
The WT pBIV127 and the two mutated BIV proviral
plasmids were used to transfect Cf2Th cells, as described
above in the Methods section. After the transfection, cells
were washed and incubated for another 48 hours to allow
viruses production. Equal amounts of ~5 × 105 copies of
the generated virions were used to infect 80% confluent
Cf2Th cells in 35 mm plates. Naïve cells were incubated
with 2 ml BIV-containing medium (WT or mutants) for
overnight in the presence of 10 μg/ml of DEAE-Dextran.
After incubation, the infected cells were washed, harvested
and the whole cellular genome was extracted, using the
“Quick-gDNA MiniPrep” (ZYMO RESEARCH). Aliquots
of these DNA preparations (2 μl) were amplified in PCR
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the N142 and N201 primers (95°C at 4 min, followed by
35 cycles of - 95°C at 30 sec, 55°C for 30 sec, 72°C for
8 min). Since the N201 primer is based on repetitive ele-
ments in canine genome [44] and the N142 is an en-
dogenous BIV primer, this PCR reaction amplified DNA
segments spanning BIV cDNA-cellular DNA. The result-
ing PCR products were diluted in ultra-pure nuclease
free-water (at the ratio of 1:100) and used as a template
for nested qPCR reactions, using the BIV-derived primers
N142 and N143, as described above. As mentioned above,
we have also tested each cDNA preparation by separate
qPCR reactions with plasmid backbone-specific primers
(oligos N162 N163) to exclude any possible minor plasmid
contaminations.
Additional file
Additional file 1: Figure S1. The PCR-based dUTPase activity assay of
the different recombinant and purified dUTPases.
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